Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily. Doses may be lower (20 mg) in some patients.
* **Pathological Hypersecretory Conditions:** Start with 40 mg orally twice daily. Doses can be increased as clinically indicated. Maximum dose is typically 240 mg daily.
## Pediatric Dosing
* **Erosive Esophagitis (12 to 17 years):** 40 mg orally once daily for up to 4 weeks.
* **Erosive Esophagitis (5 to 11 years):** 20 mg orally once daily for up to 4 weeks. For more severe erosions or refractory symptoms, 40 mg once daily may be considered.
* Dosing for younger children or for other indications is not well-established and should be guided by specialist consultation and available literature.
## Dose Adjustments
No specific dose adjustments are typically required for hepatic or renal impairment, although caution may be advised in severe hepatic dysfunction.
## Contraindications
* Known hypersensitivity to pantoprazole or any of its components.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use may be associated with increased risk of *Clostridium difficile*-associated diarrhea, bone fractures, hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** PPIs can decrease absorption of drugs like ketoconazole, itraconazole, and certain antiretrovirals.
* **Methotrexate:** Coadministration with PPIs may increase and prolong serum levels of methotrexate, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution advised with drugs like clopidogrel, citalopram, and others metabolized by this enzyme.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias).
* Monitor for signs of *Clostridium difficile* infection.
* Assess for bone fracture risk in patients on long-term therapy.
* Monitor vitamin B12 levels with prolonged use.
## Clinical Pearls
* Pantoprazole is generally less likely to interact with clopidogrel compared to omeprazole or esomeprazole due to weaker CYP2C19 inhibition.
* Administer orally 30-60 minutes before a meal.
* For IV administration, reconstitute and further dilute per manufacturer instructions.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.
